| Literature DB >> 28851814 |
Li Zhang1, Kenzie D MacIsaac2, Ting Zhou1, Pei-Yu Huang1, Chunlin Xin3, Jason R Dobson4, Kun Yu4, Derek Y Chiang4, Yue Fan3, Marc Pelletier4, Yan Wang4, Savina Jaeger5, Viveksagar Krishnamurthy Radhakrishnan4, Lellean JeBailey4, Peter Skewes-Cox6, Jing Zhang1, Wenfeng Fang1, Yan Huang1, Hongyun Zhao1, Yuanyuan Zhao1, En Li3, Bin Peng3, Alan Huang7, Glenn Dranoff4, Peter S Hammerman4, Jeffrey Engelman4, Hans Bitter4, Yi-Xin Zeng8, Yao Yao9.
Abstract
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated cancer characterized by a poor prognosis and a high level of lymphocyte infiltrate. Genetic hallmarks of NPC are not completely known but include deletion of the p16 (CDKN2A) locus and mutations in NF-κB pathway components, with a relatively low total mutational load. To better understand the genetic landscape, an integrated genomic analysis was performed using a large clinical cohort of treatment-naïve NPC tumor specimens. This genomic analysis was generally concordant with previous studies; however, three subtypes of NPC were identified by differences in immune cell gene expression, prognosis, tumor cell morphology, and genetic characteristics. A gene expression signature of proliferation was poorly prognostic and associated with either higher mutation load or specific EBV gene expression patterns in a subtype-specific manner. Finally, higher levels of stromal tumor-infiltrating lymphocytes associated with good prognosis and lower expression of a WNT and TGFβ pathway activation signature.Implications: This study represents the first integrated analysis of mutation, copy number, and gene expression data in NPC and suggests how tumor genetics and EBV infection influence the tumor microenvironment in this disease. These insights should be considered for guiding immunotherapy treatment strategies in this disease. Mol Cancer Res; 15(12); 1722-32. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28851814 DOI: 10.1158/1541-7786.MCR-17-0134
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 5.852